The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

The study analyzes the impact of COVID-19 on people with rare red blood cell disorders, identifying risk factors for severe forms of the disease.

This certification pushes our system towards a more mature model, with defined processes, clear metrics and a real focus on impact.

The nomination recognises the work she has led together with Dr. Núria Peñuelas and Dr. Miquel Vila, on the generation of new preclinical models to study Parkinson's disease.

On International Clinical Trials Day, we take a look at the institution's main data and some of the most important studies.

A study led by the Vall d'Hebron Research Institute and the Sant Joan de Déu Research Institute shows that environmental pollution increases the risk of emotional problems, while the presence of green spaces near the school reduces behavioural disorders.

The Cystic Fibrosis Unit is leading research into new genetic treatments for the disease.

The report by the Botin Foundation and Inveniam places the Institute only behind the CSIC and the UB.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

The study, led by Vall d'Hebron, is the first in Spain to analyse the relationship between pregnancy complications and the risk of long-term cardiovascular diseases.

The study reveals that if the exposure of newborns to solar radiation of sufficient intensity to provoke a skin reaction is simultaneous with the activation of the BRAFv600E gene, it can trigger an uncontrolled proliferation of cancer cells.

The work identifies variants in genes such as NFU1 that, combined with the disease-causing mutation, can accelerate kidney deterioration.

This project seeks to promote the use of artificial intelligence in stroke treatment, improving data management, transparency and clinical monitoring of patients.

The results show the need for continuous monitoring of patients to detect and manage possible adverse effects occurring months and years after treatment.

The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.

The BRIDGE project introduces a new approach that combines digital and face-to-face methods to facilitate the participation of more children in clinical trials and improve access to innovative therapies.

MouthX, developed by the company Aurax, allows people with reduced mobility in the upper extremities to have access to essential digital tools for communication, work and leisure, with the aim of improving their independence and emotional well-being.

A new diagnostic algorithm has been created to guide professionals in cases of persistent vomiting for more than four weeks.

It is part of the PROFIT Project (Personalizing the Approach to Frail Oncology Patients through Assessment and Individualized Intervention), an innovative initiative focused on providing comprehensive care for oncology patients experiencing frailty.

The collaboration will focus on several key areas of mutual interest in microbiology in particular antimicrobial resistance and stewardship.

This is a structured system that prioritizes projects with the greatest potential to ensure their viability and maximize the chances of success in their clinical application and commercialization, with a focus on benefiting patients.

The data compromised are identification data such as name, surname and ID, as well as contact information, such as email or telephone.

The study seeks to better understand blood disorders in children and young people, analyzing the role of immunological alterations to improve diagnosis and treatment.

130 schoolchildren visited the VHIR laboratories, where different scientists explained their research areas with the aim of demystifying the profession.